Idiopathic Thrombocytopenic Purpura Clinical Trial
Official title:
A Phase 2 Interventional Single Arm Study Describing Platelet Responses and ITP Remission Rates in Adult Subjects With Immune Thrombocytopenia Purpura Receiving Romiplostim
Verified date | September 2022 |
Source | Amgen |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this study is to describe the number of months with a platelet response over a 12 month treatment period and to describe ITP remission rates in adults with ITP receiving romiplostim.
Status | Completed |
Enrollment | 75 |
Est. completion date | December 26, 2013 |
Est. primary completion date | September 20, 2013 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Subject has been diagnosed with primary ITP according to the American Society of Hematology (ASH) guidelines (George et al, 1996) and previously received only 1st line therapies. First line therapy is defined as corticosteroids, immunoglobulin G (IVIG), anti-D and vinca alkaloids (used for the treatment of ITP related thrombocytopenia only). A platelet transfusion at any time during the six month period since the original diagnosis would not exclude the subject from study participation - Initial diagnosis of primary ITP within 6 months of enrollment - Age = 18 years at screening - A single platelet count = 30 x 10?/L at any time during the screening period - Subject or subject's legally acceptable representative has provided informed consent Exclusion Criteria: - Known history of a bone marrow stem cell disorder - Surgical resection of the spleen - Subject has a history of cancer or current malignancy other than basal cell carcinoma or cervical cancer in-situ with active treatment or disease within 5 years of screening - Known history of congenital thrombocytopenia - Known history of hepatitis B, hepatitis C, or human immunodeficiency virus - Positive H. pylori by urea breath test or stool antigen test at screening - Known history of systemic lupus erythematosus, Evans syndrome, or autoimmune neutropenia - Known history of antiphospholipid antibody syndrome or positive for lupus anticoagulant - Known history of disseminated intravascular coagulation, hemolytic uremic syndrome, or thrombotic thrombocytopenic purpura - Previous history of recurrent venous thromboembolism or thrombotic events or an occurrence within 5 years of enrollment. - Previous use of romiplostim, pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF), eltrombopag, recombinant human thrombopoietin (rHuTPO) or any platelet producing agent - Rituximab (for any indication) or mercaptopurine (6-MP) or anticipated use during the time of the proposed study - All hematopoietic growth factors including interleukin-11 (IL-11) (oprelvekin) within 4 weeks before the screening visit - Alkylating agents use at any time before or during the screening visit or anticipated during the time of the proposed study - Known hypersensitivity to any recombinant E. coli-derived product (eg, Infergen, Neupogen, Somatropin, and Actimmune) - Currently enrolled in another investigational device or drug study, or less than 30 days since ending another investigational device or drug study(s), or receiving other investigational agent(s) - Subject will have any other investigational procedures performed while enrolled in this clinical study - Subject is pregnant or breast feeding, or planning to become pregnant within 5 weeks after the end of treatment - Female subject of child bearing potential is not willing to use, in combination with her partner, highly effective contraception during treatment and for 4 weeks after the end of treatment - Subject has previously enrolled into a romiplostim study - Subject will not be available for protocol required study visits, to the best of the subject's and investigator's knowledge - Subject has any kind of disorder that, in the opinion of the investigator, may compromise the ability of the subject to give written informed consent and/or to comply with all required study procedures |
Country | Name | City | State |
---|---|---|---|
Australia | Research Site | Adelaide | South Australia |
Australia | Research Site | Randwick | New South Wales |
Australia | Research Site | Woolloongabba | Queensland |
Czechia | Research Site | Brno | |
Czechia | Research Site | Ostrava-Poruba | |
Czechia | Research Site | Praha 10 | |
Czechia | Research Site | Praha 2 | |
Czechia | Research Site | Praha 2 | |
France | Research Site | Bondy Cedex | |
France | Research Site | Créteil Cedex | |
France | Research Site | Dijon | |
France | Research Site | Pessac Cedex | |
France | Research Site | Toulouse Cedex 9 | |
Germany | Research Site | Dresden | |
Germany | Research Site | Duisburg | |
Germany | Research Site | Düsseldorf | |
Germany | Research Site | Köln | |
Italy | Research Site | Bari | |
Italy | Research Site | Catania | |
Italy | Research Site | Monza (MB) | |
Italy | Research Site | Napoli | |
Italy | Research Site | Novara | |
Italy | Research Site | Roma | |
Italy | Research Site | San Giovanni Rotondo FG | |
Italy | Research Site | Vicenza | |
Poland | Research Site | Gdansk | |
Poland | Research Site | Katowice | |
Poland | Research Site | Lublin | |
Poland | Research Site | Poznan | |
Poland | Research Site | Wroclaw | |
Spain | Research Site | A Coruña | Galicia |
Spain | Research Site | Alcorcon | Madrid |
Spain | Research Site | Barcelona | Cataluña |
Spain | Research Site | Majadahonda | Madrid |
Spain | Research Site | Málaga | Andalucía |
United Kingdom | Research Site | Coventry | |
United Kingdom | Research Site | Leeds | |
United Kingdom | Research Site | London | |
United Kingdom | Research Site | London | |
United Kingdom | Research Site | Oxford | |
United States | Research Site | Anaheim | California |
United States | Research Site | Bethesda | Maryland |
United States | Research Site | Boynton Beach | Florida |
United States | Research Site | Charleston | South Carolina |
United States | Research Site | Hickory | North Carolina |
United States | Research Site | Orange | California |
United States | Research Site | Philadelphia | Pennsylvania |
United States | Research Site | Richlands | Virginia |
Lead Sponsor | Collaborator |
---|---|
Amgen |
United States, Australia, Czechia, France, Germany, Italy, Poland, Spain, United Kingdom,
Cines DB, Wasser J, Rodeghiero F, Chong BH, Steurer M, Provan D, Lyons R, Garcia-Chavez J, Carpenter N, Wang X, Eisen M. Safety and efficacy of romiplostim in splenectomized and nonsplenectomized patients with primary immune thrombocytopenia. Haematologica. 2017 Aug;102(8):1342-1351. doi: 10.3324/haematol.2016.161968. Epub 2017 Apr 14. — View Citation
Kuter DJ, Arnold DM, Rodeghiero F, Janssens A, Selleslag D, Bird R, Newland A, Mayer J, Wang K, Olie R. Safety and efficacy of self-administered romiplostim in patients with immune thrombocytopenia: Results of an integrated database of five clinical trials. Am J Hematol. 2020 Jun;95(6):643-651. doi: 10.1002/ajh.25776. Epub 2020 Mar 21. — View Citation
Kuter DJ, Newland A, Chong BH, Rodeghiero F, Romero MT, Pabinger I, Chen Y, Wang K, Mehta B, Eisen M. Romiplostim in adult patients with newly diagnosed or persistent immune thrombocytopenia (ITP) for up to 1 year and in those with chronic ITP for more than 1 year: a subgroup analysis of integrated data from completed romiplostim studies. Br J Haematol. 2019 May;185(3):503-513. doi: 10.1111/bjh.15803. Epub 2019 Feb 21. — View Citation
Newland A, Godeau B, Priego V, Viallard JF, López Fernández MF, Orejudos A, Eisen M. Remission and platelet responses with romiplostim in primary immune thrombocytopenia: final results from a phase 2 study. Br J Haematol. 2016 Jan;172(2):262-73. doi: 10.1111/bjh.13827. Epub 2015 Nov 5. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of Months With Platelet Response During the 12-Month Treatment Period | The primary endpoint was the number of months a participant achieved a platelet response during the 12-month treatment period. A platelet response for any 1 month was defined as the median of platelet counts measured in the month = 50 x 10^9/L. Platelet counts within 4 weeks following a rescue medication use or following splenectomy were considered non-response. Months without any platelet count measurement were considered as months with no platelet response. | 12 months | |
Secondary | Percentage of Participants With ITP Remission | ITP remission was defined as maintaining every platelet count = 50 x 10^9/L for at least 6 months in the absence of romiplostim and any other therapies to treat ITP. | Up to 24 months | |
Secondary | Percentage of Participants With Splenectomy During the 12-month Treatment Period | If treatment with romiplostim was deemed ineffective or intolerable by the investigator, a splenectomy may have been performed. | 12 months | |
Secondary | Number of Participants With Adverse Events | An adverse event (AE) is defined as any untoward medical occurrence in a clinical trial participant. The event does not necessarily have a causal relationship with study treatment. A serious adverse event is defined as an adverse event that meets at least one of the following serious criteria: • fatal • life threatening • requires in-patient hospitalization or prolongation of existing hospitalization • results in persistent or significant disability/incapacity • congenital anomaly/birth defect • other significant medical hazard. Whether an adverse event was treatment-related (TRAE) or not was determined by investigator. | From first dose date of romiplostim to end of study (up to 24 months). | |
Secondary | Number of Participants Who Developed Antibodies to Romiplostim | The number of participants who developed antibody formation (defined as negative at baseline and positive at post-baseline, transient or persistent) to romiplostim, endogenous thrombopoietin (eTPO), and thrombopoietin mimetic peptide (TMP, the peptide component of romiplostim) was summarized. | Baseline and at end of treatment (based on response to treatment, this could occur between 12 months and approximately 18 months) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05220878 -
Comparative Study of Clinical Efficacy and Safety of GNR-069 and Nplate in Patients With ITP
|
Phase 3 | |
Completed |
NCT00451594 -
High Dose Dexamethasone Vs. Conventional Dose Prednisolone in Adult ITP
|
Phase 3 | |
Withdrawn |
NCT01276561 -
Single Incision Versus Standard Laparoscopic Splenectomy
|
N/A | |
Completed |
NCT01713855 -
Vaccine Response After Rituximab for Chronic, Severe Idiopathic Thrombocytopenic Purpura
|
N/A | |
Recruiting |
NCT03465020 -
Investigation on a Dynamic Cohort of Italian Patients With Active ITP
|
||
Completed |
NCT00603642 -
P3 Study to Evaluate Efficacy and Safety of AMG 531 in Thrombocytopenic Japanese Subjects With Immune (Idiopathic) Thrombocytopenic Purpura
|
Phase 3 | |
Not yet recruiting |
NCT04128358 -
Triple Therapy in Patients With Idiopathic Thrombocytopenic Purpura : What is Behind?
|
N/A | |
Completed |
NCT00128882 -
Treatment of Idiopathic Thrombocytopenic Purpura (ITP) With Subcutaneously Administered Anti-D
|
Phase 2 | |
Completed |
NCT01525836 -
rhTPO Combining Rituximab Versus Low-dose Rituximab in Management of ITP
|
Phase 3 | |
Completed |
NCT00888901 -
Platelet Function in Idiopathic Thrombocytopenic Purpura (ITP) Patients With Eltrombopag
|
Phase 4 | |
Completed |
NCT00828750 -
Clinical Evaluation of Eltrombopag in Chronic Idiopathic Thrombocytopenic Purpura (ITP)
|
Phase 3 | |
Completed |
NCT00625443 -
Phase 2, Parallel Group, Rollover Study of AKR-501 in Patients With ChronicITP Who Completed 28 Days of Study Treatment in Protocol 501-CL-003
|
Phase 2 | |
Completed |
NCT00475423 -
A Study of MabThera (Rituximab) in Patients With Idiopathic Thrombocytopenic Purpura.
|
Phase 2 | |
Completed |
NCT00454857 -
Retrospective & Prospective Observational Study of Patients With Immune (Idiopathic) Thrombocytopenic Purpura (ITP)
|
N/A | |
Completed |
NCT00102323 -
AMG 531 Treatment of Thrombocytopenic Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP) Refractory to Splenectomy
|
Phase 3 | |
Completed |
NCT05492409 -
Study of the Safety and Immunogenicity of Long-term GNR-069 Therapy in ITP Patients
|
Phase 3 | |
Terminated |
NCT01433978 -
A Phase 3, Multicenter, Randomized, Double-blind,Active-controlled, Parallel-group Trial With an Open-labelExtension Phase to Evaluate the Efficacy and Safety of OralE5501 Versus Eltrombopag, in Adults With Chronic ImmuneThrombocytopenia (Idiopathic Thrombocytopenic Purpura)
|
Phase 3 | |
Withdrawn |
NCT01443351 -
Long-term Safety Study of Treatment With the Thrombopoietin Agonists Eltrombopag and Romiplostim in Patients With Immune Thrombocytopenia (ITP)
|
||
Completed |
NCT01520909 -
Study of a New Medication for Childhood Chronic Immune Thrombocytopenia (ITP), a Blood Disorder of Low Platelet Counts That Can Lead to Bruising Easily, Bleeding Gums, and/or Bleeding Inside the Body.
|
Phase 3 | |
Not yet recruiting |
NCT06287567 -
Lusutrombopag in the Treatment of Immune Thrombocytopenia (ITP)
|
Phase 4 |